ClinicalTrials.gg
RecruitingNCT06112639DANCEREX-DTxUpdated Jan 10, 2025

The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders

An interventional study of DANCEREX-DTx and Multidimensional dance-based program in Sclerosis, Multiple, Neurocognitive Impairment, Mild and Neurocognitive Dysfunction, sponsored by Fondazione Don Carlo Gnocchi Onlus. Recruiting at 3 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Fondazione Don Carlo Gnocchi Onlus · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus — 7 open to participants now, 8 under way, none of them phase 3. Multiple Sclerosis · Fondazione Don Carlo Gnocchi Onlus.

Planned enrollment
2nd of 21
192 · median 48
Started
2024
with 2 others
No phase
20 of 25
4 open now
Registered
23rd of 25
by date

Among the 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 20 with no phase, and was the 23rd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

7 of the 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a new digital therapeutic solution which combines a holistic, multidimensional rehabilitation program based on dance and music with an innovative motivational system (DANCEREX-DTx) in Chronic Neurological Disorders (Multiple Sclerosis and pre-Mild Cognitive Impairment - MCI/ MCI at risk of Alzheimer's Disease). The main questions it aims to answer are 1] efficacy of the digital therapeutic solution in terms of adherence, clinical/functional measures, quality of life and surrogate measures; 2] usability and acceptability of the system.

Participants will be randomized (with an allocation ratio of 2:2:1) into the experimental group (DANCEREX - 24 sessions of multidimensional dance-based program integrated with an innovative motivational system), active comparator group (24 sessions of multidimensional dance-based program) and placebo group (24 sessions of educational program). Researchers will compare the experimental group to the other two groups to see if a digital therapeutic solution integrating a multidimensional dance-based program and motivational system is effective in increasing adherence to rehabilitation treatment.

03

Conditions studied

  • Sclerosis, Multiple
  • Neurocognitive Impairment, Mild
  • Neurocognitive Dysfunction

Keywords

  • rehabilitation
  • multiple sclerosis
  • dementia
  • digital therapeutics
  • neurocognitive dysfunction
  • MRI
  • neuroinflammation
  • telerehabilitation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age between 18 and 85 years (adult and older adult);
  2. education equal to or more than five years
  3. agreement to participate with the signature of the form;
  4. clinical diagnosis of Multiple Sclerosis (MS) according to the 2017 revised criteria of MC Donald - Expanded Disability Status Scale (EDSS) score equal or less than 4.5, R-R disease course, freedom from relapses, and treatment for at least one month, OR clinical diagnosis of pre-Mild Cognitive Impairment - MCI (Subjective Memory Complaints and/or Subjective Cognitive Complaints)/MCI at risk of Alzheimer's Disease with the Clinical Dementia Rating (CDR) scale equal or less than 0.5
  5. Normal score to a screening test for cognitive impairment ( test - MoCA test > 15.5 Santangelo et al., 2015)

Exclusion criteria

Exclusion Criteria:

  1. presence of comorbidities that prevent patients from undertaking a safe home program (e.g., balance problems, history of falls in the past 6 months, use of assistive devices for deambulation)
  2. presence of overt hearing/visual impairment
  3. for the MCI group, the absence of a caregiver/study partner able to support the participant;
  4. no living in one's own home;
  5. for the MS group, score in cerebellum function at EDSS greater than 3
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    DANCEREX Treatment

    Multidimensional dance-based program with motivational support integrated into applied game. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.

    Device: DANCEREX-DTx

  • Active comparator
    Multidimensional dance-based program

    Multidimensional dance-based program without motivational support. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.

    Device: Multidimensional dance-based program

  • Placebo comparator
    Educational Program

    Educational/informative videos on managing of clinical conditions.The program will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.

    Device: Educational Program

Interventions

  • DeviceDANCEREX-DTx

    DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions "feeds" a digital book that allows the rehabilitation experience to be placed in a narrative context.

  • DeviceMultidimensional dance-based program

    Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).

  • DeviceEducational Program

    Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.

06

What researchers measure

Primary outcomes

  1. Adherence to treatment

    Adherence to treatment, in terms of both numbers of drop-out and percentage of attended sessions on the total prescribed

    Time frame: 12 weeks of treatment

Secondary outcomes

  1. Change in global cognitive functioning and subdomains measured by Montreal Cognitive Assessment (MoCA; Conti et al., 2015)

    MoCA is a screening test for global cognitive functioning. It includes tasks involving several domains: visuospatial/executive function tests, naming, selective and sustained attention, language, abstraction, memory and orientation. High scores are indicative of better general cognitive performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  2. Change in visuoperceptual and attentional abilities measured by Trail Making Test (TMT part-A and part-B; Giovagnoli et al., 1996)

    TMT is a neuropsychological test that involves visual scanning (TMT-A) and dual-task (TMT-B). The TMT is scored by how long it takes to complete each part of the test. High execution times indicate poor performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  3. Change in visuoperceptual and attentional abilities measured by Symbol Digit Modalities Test (SDMT; Smith A., 1973; Nocentini U., 2006)

    This paper-pencil measure involves a substitution task using a coding key with nine different abstract symbols, each paired with a numeral. Below the key, a series of these symbols is presented, and the participant is asked to say the corresponding number for each symbol. The score consists of the number of correct substitutions within 90 seconds. Higher scores indicate better performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  4. Change in executive functions, including visual attention and inhibitory control of behavior measured by Stroop Test (Caffarra et al., 2002)

    The test consists of three consecutive parts that the subject must perform as quickly and accurately as possible: 1) read a list of color names on a sheet; 2) say the names of the colors of some colored spots on the sheet; 3) name the color of the ink with which the names of the colors were written. Two scores are calculated by summing the number of errors made and the time taken to complete all parts. High execution times and the number of errors indicate poor performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  5. Change in Verbal and semantic fluency measured by The Verbal Fluency and Semantic Tests (Carlesimo et al., 1996; Novelli et al., 1986).

    The Verbal Fluency and Semantic Tests are neuropsychological tests to evaluate language skills and executive functions - lexical store size, lexicon access ability, and lexical organization. The verbal fluency test requires the participant to say all words starting with a certain letter in one minute. The test comprises three letters and the score is given by the number of correct words. The semantic fluency test requires participants to say all words of a semantic category in one minute. The test includes three semantic categories and the score is given by the amount of words. Higher scores are indicative of better performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  6. Change in long term visual memory measured by Free and Cued Selective Reminding Test (FCSRT) (Frasson et al., 2011)

    FCSRT is a visual memory test that maximises encoding specificity. It assesses learning (immediate recall) and visual long-term (delayed recall) memory of visual stimuli. The administration is divided into three phases: 1) Encoding phase: naming of stimuli (three boards with four coloured stimuli each) and verification of encoding with cue; 2) Immediate recall phase: free immediate recall + recall with a cue for not recalled stimuli (this sequence is repeated three times with interference task between trials); 3) deferred recall phase (after 30 minutes of non-verbal tasks): free deferred recall + recall with a cue for not recalled stimuli. Six scores can be obtained: Immediate Free Recall (spontaneous recall in the three trials; range 0-36); Immediate Total Recall (total recall in the three trials - range 0-36); Delayed-Free Recall (range 0-12); Delayed Total Recall (range 0-12); Index of Sensitivity of Cueing (ISC) and Number of intrusions. Higher scores indicate better performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  7. Change in long term verbal memory measured by 15-Words of Rey (Carlesimo et al., 1995)

    15-Words of Rey is a test for the assessment of learning and verbal long-term memory of new information. The test is divided into 3 parts: 1\] 15 words are read to the subject. 2) immediate recall: at the end of the reading, the patient is asked to repeat as many words as possible in any order. This procedure is used with the same word list five consecutive times. 3) Delayed recall: after an interval of 15 minutes, during which visuospatial tests are performed, the patient is asked to remember as many words as possible from the list. Two scores can be obtained: Immediate Recall given by the sum of spontaneous recall in the the five trials (range 0-75) and Delayed Recall given by free deferred recall (range 0-15). Higher scores indicate better performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  8. Change in Static and dynamic balance measured by Mini-Best Test (Franchignoni et al., 2010)

    The Mini-BESTest aims to identify the disordered systems underlying the postural control responsible for poor functional balance. This tool is composed by 27 tasks (36 items in total) assessing bio-mechanical constraints, stability limits/verticality, anticipatory responses, postural responses, sensory orientation, and stability in gait. Each item is scored based on ordinal scale scoring from 0- 3 where 3 = best performances and 0 = worst performances. The total score is provided as a percentage. Higher scores are indicative of better performance.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  9. Change in Aerobic Capacity and Gait measured by 6' Minute Walking Test (6MWT)

    6' Minute Walking Test (6MWT) is has been validated as a general indicator of overall physical performance and mobility for older people (Duncan et al 1993, Harad et al 1999). The total distance walked is measured.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  10. Changes in affect measured by Positive-Negative Affect Schedule (PANAS; Watson et al, 1988)

    The PANAS is a self-report questionnaire. The list is split up into two segments, or mood scales. One scale measures a person's positive emotion and the other scale measures the negative. Each segment has ten terms, which can be rated on a scale of 1 to 5 to indicate the extent to which the respondent agrees that this applies to him. The final score of the PANAS Scale / Positive and Negative Affect Schedule (PANAS) test is the sum of the 10 terms on the positive scale and the sum of the 10 terms on the negative scale. The value assigned is positive for answers on the positive scale and negative for answers on the negative scale.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  11. Changes in Activation level of Patients measured by Patient Activation Measure 13 (PAM13; Hibbard et al., 2004)

    PAM13 is a 13-item scale that assesses a person's underlying knowledge, skills and confidence integral to managing his or her health and healthcare. PAM13 total score ranging from 0 to 100. Higher values represent a better outcome. Specifically, individuals in the lowest activation level do not yet understand the importance of their role in managing their health and have significant knowledge gaps and limited self-management skills. Individuals in the highest activation level are proactive with their health, have developed strong self- management skills, and are resilient in times of stress or change.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  12. Changes in patient's self-rated health measured by EuroQol five dimensions (5D) and five levels (5L) (The EuroQol Group, 1990; Janssen et al.,2013)

    EQ-5D-5L is a measure of health status that consists of the EQ-5D descriptive system and of the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. A total of 3125 possible health states are defined, ranging from 1111 (no problems in all dimensions) to 5555 (extreme problems in all dimensions). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labeled 'The best health you can imagine' (scored as "100") and 'The worst health you can imagine' (scored as "0").

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  13. Changes in patient's self-rated health status measured by Short Form Health Survey 36 (SF36; Ware, 2000)

    SF-36 is a short scale on health status, consisting of 36 questions subdivided into eight scales: Physical Function, Physical Role, Body Pain, General Health, Vitality, Social Function, Emotional Role and Mental Health. Each scale is transformed into a 0-100 scale on the assumption that each question carries equal weight. A lower score indicates more disability.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  14. Changes in patient's fatigue measured by Modified Fatigue Index Scale (MFIS; Kos et al., 2006)

    MFIS consists of 21 items on 5 points Likert scale (from 0 never to 4 always) to assess the physical, cognitive and psychosocial components of fatigue. Higher scores indicate a greater impact of fatigue on a person's activities.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  15. Changes in depressive symptoms measured by Beck Depression Inventory for Primary Care (BDI-PC, Steer et al., 1999)

    The BDI-PC is a 7-item questionnaire with each item rated on a 4-point scale (0-3). It is scored by summing ratings for each item (range 0-21). Higher scores indicate greater deflection of mood tone.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

  16. Changes in anxiety level measured by State-Trait Anxiety Inventory - Form Y (STAI - Y; Spielberger, 1983; Pedrabissi & Santinello, 1989)

    The STAI-Y is a commonly used measure of trait and state anxiety (20 items for each). All items are rated on a 4-point scale (from "Almost Never" to "Almost Always"). STAI is scored by summing ratings for each item (State-Anxiety: range 0-80; Trait Anxiety: range 0-80). Higher scores indicate greater anxiety.

    Time frame: Baseline, post-treatment (up to 12 weeks) and follow-up (up to 6 months from the baseline)

Other outcomes

  1. Changes in brain morphometry as detected by Magnetic Resonance Imaging Examination.

    T1weighted 3D images will be collected to test changes in brain morphometry

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

  2. Changes in structural connectivity as detected by Magnetic Resonance Imaging Examination.

    DWI sequences will be collected to detect changes in structural connectivity

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

  3. Changes in functional connectivity as detected by Magnetic Resonance Imaging Examination.

    Resting-State fMRI (Multi echo - Multi-Band) images will be collected for the assessment of brain activity at rest and functional connectivity.

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

  4. Changes in inflammatory and anti-inflammatory cytokines as measured by blood sampling

    The sera will be collected, centrifuged, stored, frozen at -80 C degrees, and shipped (when necessary) to the chosen sample-processing center. The serum will be used to measure by Enzyme-Linked ImmunoSorbent Assay (ELISA) and by Automated Immunoassay System (ELLA) the Inflammatory cytokines (TNF, IL1beta, TGF-beta, IL-6, IL-33, IL-8), and Anti-inflammatory cytokines (IL-10, IL-37),

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

  5. Changes in protein associated to downstream inflammasome activation as measured by blood sampling

    The sera will be collected, centrifuged, stored, frozen at -80 C degrees, and shipped (when necessary) to the chosen sample-processing center. The serum will be used to measure by Enzyme-Linked ImmunoSorbent Assay (ELISA) and by Automated Immunoassay System (ELLA) the protein associated to downstream inflammasome activation: IL-18, active-caspase-1(p20 kDa) for canonical NLRP3 activation and caspase- 4,5,8 for non-canonical NLRP3 activation.

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

  6. Changes in neurotrophic and neuroendocrine factors as measured by blood sampling

    The sera will be collected, centrifuged, stored, frozen at -80 C degrees, and shipped (when necessary) to the chosen sample-processing center. The serum will be used to measure by Enzyme-Linked ImmunoSorbent Assay (ELISA) and by Automated Immunoassay System (ELLA) the neurotrophic and neuroendocrine factors such as Brain-derived neurotrophic factor (BDNF), catecholamines (dopamine, noradrenaline, and adrenaline), serotonin, cortisol, acetylcholine and beta-endorphins

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

  7. Changes in neurodegenerative marker as measured by blood sampling

    The sera will be collected, centrifuged, stored, frozen at -80 C degrees, and shipped (when necessary) to the chosen sample-processing center. The serum will be used to measure by Enzyme-Linked ImmunoSorbent Assay (ELISA) and by Automated Immunoassay System (ELLA) the neurodegenerative marker such as Neurofilament-light chain (NFL)

    Time frame: Time Frame: Baseline, post-treatment (up to 12 weeks)

07

Study locations

3 of 3 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for May 2025, 15 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 15 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 1, 2023
StartActual
Jan 31, 2024
Primary completionEst.
May 1, 2025
CompletionEst.
Oct 31, 2025
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06112639
Collaborators
IRCCS Centro San Giovanni di Dio Fatebenefratelli, University of Milano Bicocca, IRCCS Centro Neurolesi Bonino Pulejo
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Jan 31, 2024
Primary completion
May 1, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Jan 10, 2025

Study contacts

Francesca Baglio, MD
Contact
fbaglio@dongnocchi.it
+390240308952
Francesca Borgnis, PhD
Contact
fborgnis@dongnocchi.it
+390240308952
Maria Pia Amato
principal investigator · IRCCS Fondazione Don Carlo Gnocchi ONLUS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion